Description: Ulisse Biomed S.p.A., a healthcare biotech company, provides diagnostic platforms and products. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It also provides various tests and reagents for sexually transmitted diseases and HPV for oropharyngeal cancer. In addition, the company's platforms also comprise NanoHybrid, a DNA/PNA based multi-modal biomolecule platform to detect specific antibodies and protein analytes directly from serum or whole blood; and Aptavir platform to develop and produce synthetic nucleic acid molecules to limit the infectivity of pathogens. Ulisse Biomed S.p.A. was founded in 2015 and is based in Udine, Italy.
Home Page: www.ulissebiomed.com
Via Cavour, 20
Udine,
UD
33100
Italy
Phone:
39 04 03 75 75 40
Officers
| Name | Title |
|---|---|
| Mr. Matteo Petti | CEO & Director |
| Ms. Bruna Marini | Co-founder, COO & Exec. Director |
| Mr. Rudy Ippodrino | Co-Founder & Chief Scientific Officer |
| Mr. Ferdinando Giuliani | Head of Bus. Devel. |
| Mr. Luigi Colombo | Exec. Director |
Exchange: MI
Country: IT
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 36.3333 |
| Price-to-Book MRQ: | 1.3193 |
| Price-to-Sales TTM: | 19.5816 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |